News & Stories

At Danaher, the importance of Diversity & Inclusion is anchored in one of our core values: The Best Team Wins. To achieve our goal of winning as the best team, we once again partnered with the Society of Women Engineers (SWE) to attract, recruit, and engage a diverse talent base to help us better serve our customers. This year from October 25-27, associates from our operating companies participated at the SWE national meeting in Austin, Texas. The team worked tirelessly to expand our future funnel of talented, high performing associate engineers by representing Danaher and our operating companies.

Pantone, a wholly owned subsidiary of X-Rite, Incorporated, and provider of professional color language standards and digital solutions, announced PANTONE 18-3838, Ultra Violet, as the Pantone Color of the Year for 2018. A dramatically provocative and thoughtful purple shade, PANTONE 18-3838 Ultra Violet communicates originality, ingenuity, and visionary thinking that points us towards the future.

2017 marks Trojan’s 40th anniversary and on the afternoon of August 30, proud Trojan friends, family and associates gathered in London, ON, to enjoy delicious food, great music, and to celebrate all that Trojan has accomplished. The event was a great success and many thanks goes out to event organizers, vendors, guest speakers and to employees past and present for their drive and dedication to the continued success of Trojan Technologies.

IDBS, a leader in enterprise scientific informatics platforms, joined Danaher's Life Sciences platform in late October. IDBS will help provide the foundation for a portfolio of life sciences informatics and knowledge management solutions that will accelerate the speed of discovering, developing and producing new drugs and therapies.

Time is critical for patients with rare diseases like hemophilia A, a genetic bleeding disorder that affects an estimated 1 in 4,000-5,000 male births. BioMarin’s newest gene therapy has the promise of delivering, in as little as a single administration, the missing gene needed to produce factor VIII (the clotting factor deficient in hemophilia A patients). Pall helped produce the drug using the power of single use technology, which compared to traditional stainless steel factories, helped cut BioMarin’s customers’ time to market by half—and meant that therapy solutions could hit the market earlier, giving patients relief.